Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Varilrix is a live attenuated vaccine developed by GSK for the prevention of varicella (chickenpox). It contains the Oka strain of the varicella-zoster virus (VZV), which is attenuated through serial passage in human diploid cell cultures. The vaccine is indicated for active immunization in healthy individuals, typically starting from 9 to 12 months of age, and is also utilized in high-risk populations such as autologous stem cell transplant recipients to prevent severe varicella infection. Varilrix works by inducing both humoral (antibody-mediated) and cellular immune responses against VZV, providing long-term protection against the disease. It is available in several formulations, including a human serum albumin (HSA)-free version.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on varicella vaccine (GSK).